Anlon Healthcare Q1 FY27 results: income ₹87.62 cr

Mandatory publication filed under SEBI LODR

Anlon Healthcare Ltd said it has completed the mandatory newspaper publication of extracts of its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The company published the extracts in the Financial Express in English and Gujarati editions on August 1, 2026. The disclosure was stated to be in compliance with Regulations 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such publications are typically part of the formal communication process once quarterly numbers are approved and filed with stock exchanges. The update signals completion of a key compliance step after the board’s approval of the quarterly financials. The company also indicated that the board meeting outcome related to approval of the results was attached with the exchange communication.

Board approval for Q1 FY27 financial results

The Board of Directors approved the unaudited financial results on July 30, 2026, for the quarter ended June 30, 2026. As per the company’s exchange intimation, the meeting agenda included approval of unaudited standalone and unaudited consolidated financial results, along with the limited review by the auditors. The company had informed BSE in advance that the meeting was scheduled for 30/07/2026 to consider these items. After approval, the company proceeded with the publication of extracts in the newspaper on August 1, 2026. The sequence reflects a standard flow: board approval, exchange submission, and newspaper publication under the applicable SEBI regulations.

Key quarterly numbers: revenue and profitability trend

For the reported period, revenue was stated at ₹87.56 crore, showing a quarter-on-quarter (QoQ) increase of 72.06% from ₹50.89 crore. The company also reported this as a year-on-year (YoY) growth of 162.94%. Operating profit was reported at ₹15.59 crore, a QoQ increase of 1.96% from ₹15.29 crore, and a YoY growth of 149.84%. Profit before depreciation and tax (PBDT) stood at ₹14.73 crore, with a QoQ change of 0.00% from ₹14.73 crore, and a YoY increase of 170.77%. Profit before tax (PBT) was ₹13.66 crore, reflecting a QoQ decrease of 5.40% from ₹14.44 crore, while still showing a YoY growth of 172.65%. Net profit was ₹8.28 crore, a QoQ decrease of 25.20% from ₹11.07 crore, and a YoY increase of 133.24%.

Consolidated snapshot provided for Q1 FY27

The company also provided a consolidated comparison for Q1 FY27 versus Q1 FY26, covering total income, EBITDA, and profit after tax. Total income for consolidated Q1 FY27 was ₹87.62 crore versus ₹33.31 crore in consolidated Q1 FY26, shown as a +163% YoY change. Consolidated EBITDA was ₹15.65 crore versus ₹6.26 crore, a +150% change. Profit after tax (PAT) was ₹8.28 crore versus ₹3.55 crore, a +133% change. These figures align with the broader set of profitability metrics and growth rates shared in the communication.

IPO proceeds utilisation disclosure

A separate disclosure cited the statutory auditors RVD & Co confirming that the ₹121.03 crore raised through the Initial Public Offer has been fully utilised as per the prospectus. The company stated there was no unutilised balance remaining at the end of the quarter. This disclosure matters for shareholders because it provides clarity on whether the funds raised were deployed within the stated objectives and timelines. It also provides a formal check from auditors on a key post-IPO compliance item.

FY26 audited results and board-approved IPO allocation

The company also referenced earlier board actions linked to audited results for the quarter and financial year ended March 31, 2026, which were approved at a board meeting held on May 29, 2026. According to the provided information, the board approved consolidated FY26 results with revenue of ₹171.97 crore and net profit of ₹29.09 crore. Separately, the company reported a 42.98% rise in consolidated total income to ₹172.22 crore for FY26, with PAT growing 41.77% to ₹29.09 crore, and noted that consolidated total income rose from ₹120.46 crore in FY25 to ₹172.22 crore in FY26. Alongside reporting performance, the board also approved a specific use of IPO proceeds, stating it would allocate ₹23.33 crore for strategic acquisitions, mergers, and manufacturing upgrades. The statutory auditors, R V D & Co., provided an unmodified opinion on the annual standalone and consolidated results.

Corporate actions: new subsidiaries approved

Anlon Healthcare said it approved the incorporation of two new subsidiaries on July 1, 2026: Anlon Medicare Private Limited and Anlon Biologics Private Limited. The total investment for these entities was stated at ₹0.175 crore (₹17.5 lakh). The update was positioned as part of the company’s corporate actions during the period and was communicated as a board-approved decision. While the disclosure does not provide operational timelines for these subsidiaries, it confirms the company’s intent to add entities under its corporate structure.

Earlier unaudited results and auditor review process

The company also referred to a board meeting held on November 11, 2025, where standalone unaudited financial results for the quarter and half-year ended September 30, 2025, were approved and submitted to the stock exchanges. In another disclosure set, Anlon Healthcare reported Q1 FY26 revenue of ₹33.2972 crore (₹3,329.72 lakh) and net profit of ₹3.5469 crore (₹354.69 lakh), and stated that the board approved those unaudited results on November 11, 2025. The results were reviewed by the Audit Committee prior to board approval. R V D & Co., Chartered Accountants, provided an independent auditor’s review report, confirming preparation in accordance with Ind AS 34.

Timeline of key disclosures and meetings

The disclosures include multiple board meetings and publications spanning FY26 and the start of FY27. The company’s Q1 FY27 results were approved on July 30, 2026, followed by newspaper publication on August 1, 2026. It also referenced earlier board activity around audited FY26 results and corporate actions. One entry provided also mentions a board meeting related to audited results, with dates listed as May 28, 2026 and May 24, 2026.

Market impact: what investors can take from the filings

The most immediate market-relevant takeaway from the disclosures is the scale of YoY growth shown in Q1 FY27 consolidated metrics, where total income was stated at ₹87.62 crore against ₹33.31 crore in Q1 FY26. At the same time, the company’s QoQ movement in profitability metrics was mixed, with PBT down 5.40% QoQ and net profit down 25.20% QoQ, even as revenue grew strongly QoQ. Investors also have a clearer compliance record because the company confirmed completion of newspaper publication under SEBI LODR and cited full utilisation of IPO proceeds of ₹121.03 crore with no quarter-end balance. The earlier FY26 audited disclosures provide broader context on full-year scale, including consolidated total income of ₹172.22 crore and net profit of ₹29.09 crore.

Analysis: why the sequence of disclosures matters

Regulations 30 and 47 filings, board approvals, and newspaper publications together form the backbone of how listed companies formally communicate financial results in India. In Anlon Healthcare’s case, the disclosures combine quarterly performance, IPO proceeds utilisation, and corporate actions such as subsidiary formation. The data points also show that while YoY growth rates were large in Q1 FY27, the QoQ decline in net profit and PBT is equally part of the reported picture and helps investors frame the quarter without relying only on YoY comparisons. The IPO proceeds note is a separate accountability checkpoint because it ties post-issue fund deployment back to the prospectus and is backed by an auditor confirmation.

Conclusion

Anlon Healthcare’s publication of Q1 FY27 financial result extracts on August 1, 2026 completes a key SEBI LODR compliance step following the board approval on July 30, 2026. The company also disclosed auditor confirmation of full utilisation of the ₹121.03 crore IPO proceeds and referenced earlier FY26 audited results and board-approved allocations. The next set of formal milestones for investors will typically be the subsequent quarterly board meeting and related stock exchange filings as per the company’s disclosure cycle.